{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:56:36Z","timestamp":1762865796042,"version":"build-2065373602"},"reference-count":76,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T00:00:00Z","timestamp":1300233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although imatinib has been used as frontline therapy for chronic myeloid leukemia (CML) for nearly a decade, current debate is focused on the incorporation of newer tyrosine kinase inhibitors (TKIs) at diagnosis in light of recent US Food and Drug Administration approval of nilotinib and dasatinib for initial therapy in chronic\u2010phase CML. Articles were identified through a PubMed search and a review of abstracts from relevant hematology congresses. Additional information was provided from the authors' libraries and expertise. With several therapies now available, it is crucial to carefully define and monitor response in patients with CML to determine whether their treatment is appropriate and is providing an optimal outcome. Different patterns of response to TKI treatment have been recognized, ranging from best\u2010case scenarios of rapid and unwavering response to difficult situations of intolerance and resistance, either primary or secondary. Patients who develop resistance to imatinib are advised to switch to second\u2010generation TKIs. Although specific mutations in the breakpoint cluster region\u2013v\u2010abl Abelson murine leukemia viral oncogene (BCR\u2010ABL) kinase domain may guide treatment selection in such scenarios, the choice is driven by other factors in the majority of patients, including the toxicity profiles of the newer TKIs as well as a patient's comorbidities. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.26062","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T10:06:16Z","timestamp":1300269976000},"page":"4343-4354","source":"Crossref","is-referenced-by-count":18,"title":["Practical management of patients with chronic myeloid leukemia"],"prefix":"10.1002","volume":"117","author":[{"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,16]]},"reference":[{"key":"e_1_2_11_2_2","unstructured":"National Comprehensive Cancer Network. NCCN: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2. 2011.http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed December 13 2010."},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_11_7_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib [abstract]","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood."},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23427"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_11_10_2","first-page":"53","article-title":"Long term outcome (progression\u2010free survival) in patients receiving nilotinib for imatinib failure who meet suboptimal response criteria according to European LeukemiaNet 2009 CML recommendations [abstract]","volume":"95","author":"Baccarani M","year":"2010","journal-title":"Haematologica."},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6999"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1112"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_11_17_2","doi-asserted-by":"crossref","first-page":"358s","DOI":"10.1200\/jco.2009.27.15_suppl.7008","article-title":"Subcutaneous omacetaxine mepesuccinate in imatinib\u2010resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation: data from an ongoing phase II\/III trial [abstract]","volume":"27","author":"Cortes JE","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_11_18_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings [abstract]","volume":"116","author":"Cortes J","year":"2010","journal-title":"Blood."},{"key":"e_1_2_11_19_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood.V116.21.208.208","article-title":"An ongoing phase 3 study of bosutinib (SKI\u2010606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia [abstract]","volume":"116","author":"Gambacorti\u2010Passerini C","year":"2010","journal-title":"Blood."},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_11_23_2","first-page":"464","article-title":"Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: clinical response, safety, and long\u2010term outcomes [abstract]","volume":"114","author":"Kantarjian HM","year":"2009","journal-title":"Blood."},{"issue":"2","key":"e_1_2_11_24_2","first-page":"256","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML\u2010AP) with imatinib resistance or intolerance: 24\u2010month follow\u2010up results of a phase 2 study [abstract]","volume":"94","author":"Hochhaus AH","year":"2009","journal-title":"Haematologica."},{"key":"e_1_2_11_25_2","first-page":"46","article-title":"Nilotinib in chronic myelogenous leukaemia in blast crisis (CML\u2010BC) patients with imatinib\u2010resistance or \u2010intolerance: updated phase 2 results","volume":"93","author":"Giles FJ","year":"2008","journal-title":"Hematologica."},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_11_31_2","first-page":"459","article-title":"Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): ENESTnd beyond 1 year [abstract]","volume":"95","author":"Hochhaus A","year":"2010","journal-title":"Haematologica."},{"key":"e_1_2_11_32_2","doi-asserted-by":"crossref","first-page":"487s","DOI":"10.1200\/jco.2010.28.15_suppl.6501","article-title":"Comparison of nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): ENESTnd beyond 1 year [abstract]","volume":"28","author":"Larson RA","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_11_33_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) in the DASISION trial: 18\u2010month follow\u2010up [abstract]","volume":"116","author":"Shah N","year":"2010","journal-title":"Blood."},{"key":"e_1_2_11_34_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) [abstract]","volume":"116","author":"Hughes TP","year":"2010","journal-title":"Blood."},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"volume-title":"Sprycel (Dasatinib) [Package Insert]","year":"2010","key":"e_1_2_11_39_2"},{"key":"e_1_2_11_40_2","first-page":"143","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML\u2010CP) [abstract]","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood."},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511292103"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4732"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0110-4"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01501.x"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0565-1"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.46"},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010496"},{"volume-title":"Tasigna (Nilotinib) [Package Insert]","year":"2010","key":"e_1_2_11_48_2"},{"volume-title":"Gleevec (Imatinib) [Package Insert]","year":"2008","key":"e_1_2_11_49_2"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-104281"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)80608-6"},{"key":"e_1_2_11_53_2","first-page":"56","article-title":"Minimal cross\u2010intolerance between nilotinib and imatinib in patients with imatinib\u2010intolerant chronic myelogenous leukaemia (CML) in chronic phase (CP) or accelerated phase (AP)","volume":"93","author":"Hochhaus A","year":"2008","journal-title":"Hematologica."},{"key":"e_1_2_11_54_2","first-page":"51","article-title":"Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia in chronic phase (CML\u2010CP) who are intolerant to imatinib\u2014a retrospective safety analysis [abstract]","volume":"93","author":"Guilhot F","year":"2008","journal-title":"Haematologica."},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_11_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"key":"e_1_2_11_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.03.020"},{"key":"e_1_2_11_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070144"},{"key":"e_1_2_11_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.01.018"},{"key":"e_1_2_11_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.01.004"},{"volume-title":"Dasatinib (BMS\u201035825) Oncologic Drug Advisory Committee Briefing Document NDA 21\u201096","year":"2006","author":"US Food and Drug Administration (FDA)","key":"e_1_2_11_64_2"},{"key":"e_1_2_11_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180604"},{"key":"e_1_2_11_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"},{"issue":"2","key":"e_1_2_11_67_2","first-page":"256","article-title":"Age has no impact on outcome of early chronic phase, Ph\u2010positive CML, imatinib treated patients: a nationwide analysis on 559 cases of the GIMEMA CML WP [abstract]","volume":"94","author":"Gugliotta G","year":"2009","journal-title":"Haematologica."},{"key":"e_1_2_11_68_2","first-page":"1272","article-title":"Efficacy and safety of nilotinib in elderly patients with imatinib\u2010resistant or \u2010intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub\u2010analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study [abstract]","volume":"114","author":"le Coutre PD","year":"2009","journal-title":"Blood."},{"key":"e_1_2_11_69_2","first-page":"349","article-title":"Efficacy and safety profile of dasatinib in a subset of very elderly patients with chronic myeloid leukemia (CML) resistant\/intolerant to imatinib [abstract]","volume":"95","author":"Cavazzini F","year":"2010","journal-title":"Haematologica."},{"key":"e_1_2_11_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032"},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404051"},{"key":"e_1_2_11_72_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-280206"},{"key":"e_1_2_11_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_2_11_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_11_75_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood.V116.21.209.209","article-title":"Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL\u2010II trial [abstract]","volume":"116","author":"Yeung DT","year":"2010","journal-title":"Blood."},{"key":"e_1_2_11_76_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"e_1_2_11_77_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26062","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:30:46Z","timestamp":1760265046000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,16]]},"references-count":76,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1002\/cncr.26062"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26062","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2011,3,16]]}}}